Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ebola vaccine doses will be ready in 2015
Vaccination
Trials of ebola vaccines have already begun in the US, UK and Mali.
Parties working together to finalise fastest approach for developing and distributing vaccines

Millions of doses of experimental Ebola vaccines will be available in 2015, the World Health Organisation (WHO) has announced.

The commitment was made during a WHO meeting last week with high-ranking government representatives from Ebola-affected countries and development partners, funding agencies, vaccine manufacturers, civil society and regulatory agencies.

During the meeting, the participants discussed and agreed on how to fast-track testing and deployment of vaccines in ample numbers to impact the Ebola epidemic.

The participants agreed that phase one clinical trials of the most advanced vaccines will be available by December 2014. They also agreed that efficacy trials in affected countries also begin in this timeframe, with protocols adapted to take into consideration safety and immunogenicity results as they become available.

Pharmaceutical companies developing the vaccines committed to scale-up production capacity for millions of doses to be available in 2015, with several hundred thousand to be ready before the end of the first half of the year. Regulatory authorities in both Africa and countries where the vaccines are manufactured committed to supporting this aim by working under extremely short deadlines.

It was also decided that community engagement is key and work should be increased urgently in partnership between local communities international organisations, NGOs and national governments.

WHO say that vaccines may have a major impact on further evolution of the epidemic. All parties will be working together to finalise the quickest approach for developing and distributing vaccines, so that effective treatments and prevention methods are welcomed and shared far and wide by the communities themselves.  

Trials of vaccines have already begun in the US, UK and Mali, and are beginning in Germany, Gabon, Switzerland and Kenya to establish safety and dose level.

Marie-Paule Kieny, WHO's assistant director-general of health systems and innovation, said: "As we accelerate in a matter of weeks a process that typically takes years, we are ensuring that safety remains the top priority, with production speed and capacity a close second."

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.